AT1 Atomo Diagnostics Limited
Healthcare · Medical Devices
· website
$0.02
52wk 0.02 – 0.05
Overall
67.1
Value
92.3
Growth
100.0
Health
100.0
Quality
0.0
Momentum
13.1
Dividend
—
Price
About Atomo Diagnostics Limited
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-testing programs; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | -2.7% |
| 1 month | 5.9% |
| 3 months | 5.9% |
| 6 months | -37.9% |
| 1 year | -40.0% |
| 3 years | -18.2% |
Risk
| Volatility (1y ann.) | 84.1% |
| Beta vs ASX 200 | 0.39 |
| Sharpe (1y) | -0.24 |
| VaR 95% (1-day) | -7.7% |
| Max drawdown (1y) | -63.6% |
| Off 1-year high | -59.1% |
Technicals
| RSI(14) | 62 |
| vs 50DMA | 1.2% |
| vs 200DMA | -31.3% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
92.3
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
83
Price / Sales
76
Growth
100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
100
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
13.1
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
56
Position in 52-week range
6
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$16.24M
P/E (trailing)
—
P/E (forward)
-0.02
EPS (trailing)
0.00
Dividend yield
—
Payout ratio
0.0%
Beta
1.11
EV / EBITDA
-3.16
Price / Book
2.00
ROE
-47.9%
Operating margin
-82.1%
Net margin
-65.9%
Total cash
$3.71M
Total debt
$373,082
Current ratio
3.04
Debt / Equity
0.05
Free cash flow
$-2.78M
Avg volume
735,899
Latest annual results
(FY ending 30 Jun 2026)
- Revenue$5.23M
- Gross profit$1.77M
- Operating income-$5.79M
- Net income-$3.51M
- Diluted EPS—
- Free cash flow-$3.40M
- Net debt-$3.34M